ARID1A and urinary bladder carcinoma: Regarding the high frequency of genetic ARID1A alterations in urothelial bladder and a demonstrated loss of ARID1A protein expression, predominantly in a subset of high-grade bladder carcinomas including CIS, it seems worthwile to promote research on the identification of specific vulnerabilities conferred by ARID1A-deficiency.